This module uses fundamental data of Sirona Biochem to approximate the value of its Beneish M Score. Sirona Biochem M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sirona Biochem Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Sirona
Beneish M Score
Sale Purchase Of Stock
Investments
Change In Cash
Net Borrowings
Total Cashflows From Investing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Other Cashflows From Financing Activities
End Period Cash Flow
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Stock Based Compensation
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Retained Earnings
Accounts Payable
Cash
Long Term Debt
Net Receivables
Short Term Investments
Other Current Assets
Other Stockholder Equity
Total Liab
Deferred Long Term Liab
Short Long Term Debt
Total Current Assets
Short Term Debt
Intangible Assets
Common Stock
Property Plant Equipment
Good Will
Non Current Assets Total
Non Current Liabilities Total
Capital Lease Obligations
Net Debt
Common Stock Shares Outstanding
Net Invested Capital
Net Working Capital
Capital Stock
Property Plant And Equipment Gross
Property Plant And Equipment Net
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Cost Of Revenue
Non Recurring
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Interest Income
Tax Provision
Ebitda
Reconciled Depreciation
Probability Of Bankruptcy
At this time, Sirona Biochem's Long Term Debt is fairly stable compared to the past year. Short Term Debt is likely to climb to about 586.1 K in 2024, whereas Short and Long Term Debt is likely to drop slightly above 536.1 K in 2024.
At this time, Sirona Biochem's M Score is inapplicable. The earnings manipulation may begin if Sirona Biochem's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Sirona Biochem executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Sirona Biochem's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Sirona Biochem's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Sirona Biochem's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Sirona Biochem in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Sirona Biochem's degree of accounting gimmicks and manipulations.
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Reconciled Depreciation
8,301.2
At this time, Sirona Biochem's Reconciled Depreciation is fairly stable compared to the past year.
Sirona Biochem Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Sirona Biochem. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
The Macroaxis Fundamental Analysis modules help investors analyze Sirona Biochem Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sirona Biochem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sirona Biochem Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
When running Sirona Biochem's price analysis, check to measure Sirona Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sirona Biochem is operating at the current time. Most of Sirona Biochem's value examination focuses on studying past and present price action to predict the probability of Sirona Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sirona Biochem's price. Additionally, you may evaluate how the addition of Sirona Biochem to your portfolios can decrease your overall portfolio volatility.